000078116 001__ 78116
000078116 005__ 20220405150412.0
000078116 0247_ $$2doi$$a10.1016/j.nrl.2018.01.008
000078116 0248_ $$2sideral$$a110853
000078116 037__ $$aART-2018-110853
000078116 041__ $$aspa
000078116 100__ $$aMonge Galindo, L.
000078116 245__ $$aNeuritis óptica en pediatría: Experiencia en 27 años y protocolo de actuación
000078116 260__ $$c2018
000078116 5060_ $$aAccess copy available to the general public$$fUnrestricted
000078116 5203_ $$aIntroducción y objetivos: Se presenta nuestra experiencia en neuritis óptica (ON) y se elabora un protocolo diagnóstico-terapéutico, que contempla descartar otras causas, principalmente infecciosas y se elabora una hoja informativa para padres.
Material y método: Estudio descriptivo retrospectivo de los pacientes con ON en 27 años (1990-2017). Revisión de evidencia científica para elaboración del protocolo y hoja informativa.
Resultados: En nuestra sección de neuropediatría se valoraron 20.744 niños en 27 años, 14 con ON: 8 ON aisladas, una esclerosis múltiple (EM), un episodio clínicamente aislado (CIS), 3 encefalomielitis agudas diseminadas y un paciente con ON aislada que el año anterior había sufrido una encefalomielitis aguda diseminada. Edades entre 4-13 años, 50% varones. Mayores de 10 años, 8 pacientes: 7 ON aisladas y un EM. Bilaterales 9, retrobulbares 3. Resonancia magnética cerebral normal en 7, solo afectación del nervio óptico en 2 y con desmielinización del SNC en 5 casos. Recibieron corticoterapia 13/14. Un caso vacunado de meningococo-C el mes anterior. Todos evolucionaron favorablemente, salvo la EM. Se presentan el protocolo y la hoja de información.
Conclusiones: Habitual curso favorable. En niños a partir de 10 años, con factores de riesgo de desarrollar EM o neuromielitis óptica (presencia de hiperseñales en RM cerebral, bandas oligoclonales, anti-NMO, recurrencia de ON), se consensúa con Neurología el inicio de tratamiento inmunomodulador. Utilidad del protocolo para la toma de decisiones diagnósticas, de seguimiento y tratamiento, de una patología poco frecuente pero con posibles repercusiones importantes. Importancia de la protocolización y hojas informativas.
Introduction and objective: In this article, we present our experience on optic neuritis (ON) and provide a diagnostic/therapeutic protocol, intended to rule out other aetiologies (particularly infection), and a fact sheet for parents.
Material and methods: We conducted a descriptive, retrospective study of patients with ON over a 27-year period (1990-2017). A review of the available scientific evidence was performed in order to draft the protocol and fact sheet.
Results: Our neuropaediatrics department has assessed 20, 744 patients in the last 27 years, of whom 14 were diagnosed with ON: 8 had isolated ON, 1 had multiple sclerosis (MS), 1 had clinically isolated syndrome (CIS), 3 had acute disseminated encephalomyelitis, and 1 had isolated ON and a history of acute disseminated encephalomyelitis one year previously. Patients’ age range was 4-13 years; 50% were boys. Eight patients were aged over 10: 7 had isolated ON and 1 had MS. Nine patients had bilateral ON, and 3 had retrobulbar ON. MRI results were normal in 7 patients and showed involvement of the optic nerve only in 2 patients and optic nerve involvement + central nervous system demyelination in 5. Thirteen patients received corticosteroids. One patient had been vaccinated against meningococcus-C the previous month. Progression was favourable, except in the patient with MS. A management protocol and fact sheet are provided.
Conclusions: ON usually has a favourable clinical course. In children aged older than 10 years with risk factors for MS or optic neuromyelitis (hyperintensity on brain MRI, oligoclonal bands, anti-NMO antibody positivity, ON recurrence), the initiation of immunomodulatory treatment should be agreed with the neurology department. The protocol is useful for diagnostic decision-making, follow-up, and treatment of this rare disease with potentially major repercussions. The use of protocols and fact sheets is important.
000078116 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000078116 590__ $$a2.038$$b2018
000078116 591__ $$aCLINICAL NEUROLOGY$$b136 / 199 = 0.683$$c2018$$dQ3$$eT3
000078116 592__ $$a0.47$$b2018
000078116 593__ $$aNeurology (clinical)$$c2018$$dQ2
000078116 593__ $$aMedicine (miscellaneous)$$c2018$$dQ2
000078116 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/submittedVersion
000078116 700__ $$aMartínez de Morentín, A.L.
000078116 700__ $$0(orcid)0000-0002-1777-0349$$aPueyo Royo, V.$$uUniversidad de Zaragoza
000078116 700__ $$aGarcía Iñiguez, J.P.
000078116 700__ $$aSánchez Marco, S.
000078116 700__ $$0(orcid)0000-0002-1876-1495$$aLópez-Pisón, J.$$uUniversidad de Zaragoza
000078116 700__ $$0(orcid)0000-0002-9336-780X$$aPeña-Segura, J.L.$$uUniversidad de Zaragoza
000078116 7102_ $$11004$$2646$$aUniversidad de Zaragoza$$bDpto. Cirugía,Ginecol.Obstetr.$$cÁrea Oftalmología
000078116 7102_ $$11010$$2670$$aUniversidad de Zaragoza$$bDpto. Pediatría Radiol.Med.Fís$$cÁrea Pediatría
000078116 773__ $$g36, 4 (2018), 253-261$$pNeurología (Barc.)$$tNEUROLOGIA$$x0213-4853
000078116 8564_ $$s341098$$uhttps://zaguan.unizar.es/record/78116/files/texto_completo.pdf$$yVersión publicada
000078116 8564_ $$s91119$$uhttps://zaguan.unizar.es/record/78116/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000078116 909CO $$ooai:zaguan.unizar.es:78116$$particulos$$pdriver
000078116 951__ $$a2022-04-05-14:35:25
000078116 980__ $$aARTICLE